All In Biotech

Drug Trial Radar · NCT03815695

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

A Randomized, Placebo-controlled, Double Blind, Single Ascending and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

Last checked: Nov 19, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Dec 11, 2018

Primary completion

Dec 17, 2021

Study completion Dec 17, 2021

Sponsor

Lead sponsor
Forma Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Jan 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

FT-4202 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of FT-4202 in the context of Phase 1 studies in healthy volunteers and sickle cell disease patients. The effects of food on the absorption of FT-4202 will also be evaluated in healthy volunteers.

Conditions

  • Healthy Volunteers
  • Sickle Cell Disease

Interventions

  • FT-4202/PlaceboDrug

    Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, frequency, and severity of adverse events (AEs) per CTCAE v5.0 of a single ascending dose and multiple ascending doses of FT-4202 in adult healthy volunteers and SCD patients.Time frame: Up to 3 weeks of monitoring
  2. Maximum observed plasma concentration (Cmax)Time frame: Up to 3 weeks of testing
  3. Time to maximum observed plasma concentration (Tmax)Time frame: Up to 3 weeks of testing
  4. Area under the plasma concentration-time curve from time zero until the 24-hour time point (AUC0-24)Time frame: Up to 3 weeks of testing
  5. Area under the plasma concentration-time curve from time zero until the last quantifiable time point (AUC0-last)Time frame: Up to 3 weeks of testing
  6. Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf)Time frame: Up to 3 weeks of testing
  7. Terminal elimination half-life (t1/2)Time frame: Up to 3 weeks of testing
  8. Apparent clearance (CL/F)Time frame: Up to 3 weeks of testing
  9. Apparent volume of distribution (Vd/F)Time frame: Up to 3 weeks of testing
  10. Terminal disposition rate constant (Lz)Time frame: Up to 3 weeks of testing
  11. Renal clearance (ClR)Time frame: Up to 3 weeks of testing

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Woodland International Research Group (SCD subjects only)

    Little Rock, Arkansas

  • Collaborative Neuroscience Research, LLC (SCD subjects only)

    Long Beach, California

  • Pacific Research Partners (SCD subjects only)

    Oakland, California

  • UCSF Benioff Children's Hospital Oakland (SCD subjects only)

    Oakland, California

  • Advanced Pharma CR, LLC (SCD subjects only)

    Miami, Florida

  • Children's Healthcare of Atlanta (SCD subjects only)

    Atlanta, Georgia

  • Augusta University Medical Center (SCD subjects only)

    Augusta, Georgia

  • University of Illinois at Chicago (SCD subjects only)

    Chicago, Illinois

  • University of Maryland, Greenebaum Comprehensive Cancer Center (SCD subjects only)

    Baltimore, Maryland

  • Columbia University Medical Center (SCD subjects only)

    New York, New York

  • Levine Cancer Institute (SCD subjects only)

    Charlotte, North Carolina

  • Duke University Medical Center (SCD subjects only)

    Durham, North Carolina

  • University of Cincinnati Medical Center (SCD subjects only)

    Cincinnati, Ohio

  • Medpace Clinical Pharmacology Unit (Healthy Volunteers only)

    Cincinnati, Ohio

  • Cincinnati Children's Hospital Medical Center (SCD subjects only)

    Cincinnati, Ohio

  • Lynn Institute of Tulsa (SCD subjects only)

    Tulsa, Oklahoma

  • St. Jude Children's Research Hospital (SCD subjects only)

    Memphis, Tennessee

  • The University of Texas Health Science Center at Houston (SCD subjects only)

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.